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A B S T R A C T  
Objective: The objective of this study is to compare the efficacy and safety of Intralesional Meglumine Antimoniate and 
Intralesional Artemether in the Treatment of Cutaneous Leishmaniasis. 
Patients and Methods: Total 168 patients of cutaneous leishmaniasis were assigned randomly and equally to 
intralesional meglumine antimoniate (group A) and intralesional artemether (group B). The study outcome was measured 
after 6 weeks of therapy and treatment was considered efficacious if the lesion reduced more than 75% from its baseline 
size. The side effects in terms of pain, redness and swelling at the site of injection, fever, hepatitis and renal impairment 
were also noted. 
Results: Intralesional meglumine antimoniate achieved complete healing in 75 (89.3%) cases compared to 62 (73.8%) 
cases in intralesional artemether (p= 0.01). 
Conclusion: Intralesional meglumine antimoniate is better than intralesional artemether in the treatment of cutaneous 
leishmaniasis. Both drugs were found safe and no significant side effects were noted. 
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I n t r o d u c t i o n  
 
Leishmaniasis is one of the protozoan skin infections 
caused by an intracellular parasite of the genus 
Leishmania which is transferred by the bite of sand fly, 
Phlebotomine. According to WHO, disease is native in 98 
countries, having 350 million people at risk and currently 1 
to 1.3 million cases are reported yearly.1  The disease is 
endemic in Pakistan with a rising incidence in northern 
hilly areas and in Lasbella and Makran coastal areas in 
the southern parts of the country along with scattered foci 
in Punjab, KPK and Azad Kashmir.2 The clinical 
continuum of leishmaniasis varies from cutaneous 
disease to disfiguring mucocutaneous disease and to a 
deadly systemic ailment. Cutaneous leishmaniasis 
generally heals spontaneously within a year, but resulting 
morbidity and disfiguring scar make it a serious health 
hazard especially in the endemic areas. Pentavalent 
antimony compounds like meglumine antimoniate and 
sodium stibogluconate are considered to be the mainstay 
of therapy for cutaneous leishmaniasis.3 A study 
documented that efficacy of intralesional Glucantime was 
80%, and was significantly higher than the 33.3% rate of 
healing in the group treated with intralesional 2% zinc 
sulfate.4 However there have been several reports of 
emerging resistance to antimony compounds.5, 6 
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Artemether is an established drug for the treatment of 
malaria and this drug has also been found to be effective 
against cutaneous leishmaniasis caused by leishmania 
major in BALB/c mice.7 A study showed that injection 
artemisinin when injected within the lesion of cutaneous 
leishmaniasis along-with sodium stibogluconate is 
effective in reducing the duration of healing in cutaneous 
leishmaniasis in 93.2% of individuals.8 It was considered 
that intralesional meglumine antimoniate is more effective 
and safer than intralesional artemether.This study was 
designed to compare the efficacy and safety of 
Intralesional Meglumine Antimoniate and Intralesional 
Artemether in the treatment of Cutaneous Leishmaniasis. 
P a t i e n t s  a n d  M e t h o d s  
This randomized controlled trial was carried out in 
Dermatology department, Pakistan Institute of Medical 
Sciences, Islamabad from 1st January 2015 to 31st 
October 2015.  Total 168 patients of cutaneous 
leishmaniasis were registered. Patients above 14 years of 
age of either gender, having lesion duration for less than 
two months and lesion count equal to or less than three 
were included in the study. Those patients taking 
antileishmanial therapy within last two months, pregnant 
or lactating females, patients with hepatic or renal 
derangement, those with known allergy to the drug used 
and those having lesions localized to or near the joints 
were excluded. Permission was taken from the hospital’s 
ethical committee. Skin biopsy was done for making a 
diagnosis. Venous blood samples were collected for 
baseline LFTs and Serum creatinine. The patients were 
divided randomly into two groups. Group A was given 
intralesional meglumine antimoniate, till blanching of 
lesion, weekly for 6 weeks and group B received 
intralesional artemether in same dosage schedule. 
The study outcome was measured after 6 weeks of 
therapy and treatment was considered efficacious if the 
lesion reduced more than 75% from its baseline size. The 
data was analyzed with the help of Statistical Package for 
Social Sciences (SPSS) version 17. Chi square test was 
applied to compare complete healing after 6 weeks and 
safety (pain, hepatitis and renal impairment) between two 
groups. P value <0.05 was considered significant.  
 
R e s u l t s  
The mean age of patients was 27.3±12.1 in group A and 
28.2±13.2 years in group B. The mean number of lesions 
was 1.2±0.43 in group A and 1.1±0.42 in group B. The 
lesion size was found to be 10.6±7.4 cm in group A and 
6.7±5.5 cm in group B (Table 1). The efficacy of 
interventions was measured after 6 weeks of treatment in 
terms of 75% reduction in size of lesion from its pre 
intervention measurement. In this study it was found that 
the drug used in group A was significantly more 
efficacious than group B in the treatment of cutaneous 
leishmeniasis (p-value, 0.01) (Table 2) 
D i s c u s s i o n  
Cutaneous leishmaniasis is not a life threatening illness 
and it does not cause significant morbidity, however the 
disfiguring scar caused by it, is a source of mental 
distress and thus impairs quality of life of the patients. For 
this reason, dermatologists always try to treat it, using 
different treatment modalities. The mean age of patients 
was 27.3 + 12.1 in group A and 28.2 + 13.2 years in 
group B and was found comparable. In a comparative 
study by Anderson EA on meglumine antimoniate the 
mean age of patients was found to be 30 years.9   
 
Table 1: Cutaneous lesions before treatment in the 
two study groups 
 Group A 
(n=84) 
Group B 
(n=84) 
p-value 
No. of lesions 
Mean + SD 1.2 + 0.43 1.1 + 0.42 0.63 
Lesion size (cm2) 
Mean + SD 10.6 + 7.4 6.7 + 5.5 0.02 
 
Table 2: Comparison of efficacy of interventions 
between the two study groups 
Efficacy (complete 
healing after 6 
weeks) 
Group A 
(n=84) 
Group B 
(n=84) 
p-value 
Achieved 75 (89.3%) 62 (73.8%)  
0.01 
Not achieved 9 (10.7%) 22 (26.2%) 
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Another RCT (randomized control trial) by 
Nilforoushzadeh MA on comparison of meglumine 
antimoniate alone with combination of trichloroacetic Acid 
50% and intralesional meglumine antimoniate in the 
treatment of acute cutaneous leishmaniasis witnessed the 
mean age of their patients to be 11.0 years with age 
range of 5 to 32 years as they also enrolled paediatric 
and adolescent age groups.10 A local study by Jamal Q et 
al witnessed that most of their cases of leishmaniasis 
were between 11 and 20 years.11 
 In the present study, male gender was predominantly 
affected by cutaneous leshmaniasis in both genders. A 
study by Al Samarai and Abolaidi witnessed a similar 
trend with male majority in their study.12 Other previous 
studies also reported male preponderance, however, 
there are contrast reports as well where both genders 
have been found equally affected and even in some trials 
female gender was found predominant.13 In this study 
most of the lesions were found on forearm, followed by 
legs and face whereas the mean number of lesions were 
1.2 per patient. Goyonlo VM witnessed that most of their 
patients had lesions on head and neck followed by upper 
limbs.14 In the present study Intralesional meglumine 
antimoniate achieved complete healing in (89.3%) cases 
compared to (73.8%) cases in Intralesional arthemeter 
group after 6 weeks of treatment and this difference was 
significant (p-value,0.01). We could not find any study 
comparing intralesional meglumine antimoniate and 
intralesional artemether in humans, however, studies on 
animals (mice) were available. 
In a study, conducted by Ghaffarifar F et al, the 
antiparasitic activity of artemisinin on L.major, both in vitro 
and in vivo, was assessed by finding the cytokine pattern 
as well as the percentage of apoptosis induced by 
artemisinin. It was concluded that artemisinin induces 
cytotoxic effects on L.major via apoptosis related 
mechanism.15 it was reported that oral artemether is an 
effective and simple method and may be used to treat 
visceral leishmaniasis.16 The current study has many 
advantages, firstly, there have been very few studies 
on cutaneous leishmaniasis nationally and 
internationally and this study is certainly very 
informative in this regard. Secondly, two therapeutic 
drugs i.e. intralesional meglumine antimoniate and 
intralesional artemether for the management were 
investigated. Thirdly, a reasonable number of study 
population was enrolled in both study groups. 
Although, the current study found no local side 
effects (pain, redness and swelling at the site of 
injection), fever and renal impairment with both 
interventions, there were 2 cases of Hepatitis in 
meglumine antimoniate and 1 case in artemether 
group. Intralesional artemether can be considered as a 
safe and effective treatment option in localized cutaneous 
leishmaniasis. Although the cure rate was better in the 
intralesional meglumine antimoniate group, but 
intralesional artemether is much cheaper, readily 
available and at the same time is effective and safe. 
There is a need to conduct further comparative trials on 
artemether and meglumine antimoniate, so that findings 
of current study could be validated. 
C o n c l u s i o n  
Intralesional meglumine antimoniate is superior to 
intralesional artemether in the management of cutaneous 
Leishmaniasis. Both drugs have very few toxic effects and 
were found safe for treatment. 
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